导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.45% | 1617/4773 |
| 近一周 | -2.13% | 3437/5465 |
| 近一月 | -5.24% | 3682/5421 |
| 近一季 | -10.42% | 3751/5231 |
| 近半年 | -2.26% | 2074/4920 |
| 近一年 | 8.93% | 1259/4394 |
| 近两年 | 66.45% | 1078/2954 |
| 近三年 | 33.35% | 955/2253 |
| 成立以来 | 48.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.16% 1622/4961 |
18.11% 1417/5312 |
- - |
- - |
| 2025 | 31.91% 1206/4813 |
1.73% 1561/3635 |
0.60% 2604/4076 |
29.22% 1233/4524 |
-0.25% 2437/4813 |
| 2024 | 4.76% 1865/3463 |
-4.25% 1625/2808 |
-1.80% 1109/3014 |
12.64% 2306/3129 |
-1.09% 1587/3463 |
| 2023 | -17.85% 1763/2656 |
4.87% 860/2280 |
-6.38% 1629/2385 |
-10.49% 2003/2515 |
-6.52% 1811/2655 |
| 2022 | -23.89% 1173/2207 |
-14.41% 942/1919 |
4.64% 988/2016 |
-15.14% 1226/2113 |
0.15% 1534/2208 |
| 2021 | -1.00% 775/1822 |
-6.86% 1043/1255 |
9.57% 544/1330 |
-5.46% 808/1466 |
2.62% 553/1822 |
| 2020 | 36.58% 393/1250 |
-1.99% 251/1028 |
20.53% 271/1067 |
7.21% 797/1164 |
7.83% 693/1184 |
| 2019 | 33.74% 426/1092 |
29.74% 267/754 |
-9.80% 691/804 |
5.03% 169/850 |
8.81% 285/918 |
| 2018 | -35.88% 581/834 |
- - |
- - |
- - |
-15.74% 615/691 |
| 2017 | 8.67% 313/714 |
- - |
- - |
- - |
- - |
| 2016 | -25.58% 484/605 |
- - |
- - |
- - |
- - |
| 2015 | 40.23% 44/575 |
- - |
- - |
- - |
- - |
| 2014 | 15.49% 198/237 |
- - |
- - |
- - |
- - |
| 2013 | 16.27% 22/186 |
- - |
- - |
- - |
- - |
| 2012 | -8.71% 139/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华富中小企业100指数增强 VS. 长安沪深300非周期A(740101) |